The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
The company — a spinout of the New York Genome Center — said it will use the funding in part to develop its technologies for new applications in agriculture.
The company said it intends to use the proceeds of the placement to continue work on its microfluidic PCR-based platform for pathogen detection.
The company's lead product is a software platform that uses a patient's pharmacogenetic and other medical data to help personalize drug selection.
The firm's lead product is a blood-based assay, called Alibrex, which uses PCR technology to monitor stage IV solid tumor cancer therapy.
The company plans to use the funds to support development of an early cancer detection test and expansion of its CDx sales force.
The firm has developed a microbiome analytics platform for supply chain management that combines next-generation sequencing and artificial intelligence.
The genome informatics company will apply the new capital to deploy the DNAnexus Apollo platform for multi-omics data science exploration, analysis, and discovery.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.
Newsweek discusses the privacy issues raised by digital medicine.
A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.
In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.
Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.